The single-use bioprocessing market is expected to grow at a CAGR of 14.5% during the forecast period. The market is estimated to be around USD 17.7 billion in 2024 and is projected to reach USD 34.9 billion by 2029. Growing biologics & biosimilars market, need for low capital investment, a surge in single-use bioprocessing adoption among CDMOs & CMOs, and advantages such as increased productivity & reduced risk of cross contamination, are some factors responsible for the growth of the market. On the other hand, issues related to leachables & extractables, regulatory compliance, and discussions about PFAS restrictions are hampering the market growth.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297
Based on products, the single-use bioprocessing market is segmented into equipment and consumables. The consumables segment accounted for the largest share and is also estimated to grow at the highest CAGR of the single-use bioprocessing market. This can be attributed to their repeated purchase, higher usage, frequent replacement, and broad application range.
Based on application, the single-use bioprocessing market is segmented into cell culture, filtration, purification, mixing, storage & transfer, and other applications. The filtration segment accounted for the largest share of the single-use bioprocessing market. The large share of this segment can be attributed to the wide use of equipment for various filtration applications in the pharmaceutical industry, increased filtration requirements in the biopharmaceutical industry, and the higher requirement for these filters compared to consumables and filtration accessories.
Based on workflow, the single-use bioprocessing market is segmented into upstream and downstream bioprocessing. The growth of the single-use bioprocessing market for upstream bioprocesses is driven by technological advancements and strategic collaborations between industry players. For instance, in June 2023, Culture Biosciences and Cytiva collaborated to introduce new bioprocess solutions that leverage digitization, in-silico approaches, and virtual monitoring and control of experiments. This collaboration revolutionized upstream processing by providing customers unprecedented access to cutting-edge technologies and methodologies, fueling the demand for advanced bioprocessing solutions.
Based on molecule type, the single-use bioprocessing market is segmented into monoclonal antibodies (mAbs), vaccines, therapeutic proteins & peptides, and cell & gene therapies. mAbs accounted for the largest share of the single-use bioprocessing market. The large share is attributed to the increasing pharmaceutical R&D drug pipeline, increasing incidence of cancer, and rising usage & demand for cancer therapy.
Based on the end user, the single-use bioprocessing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and CMOs & CROs. In 2023, pharmaceutical & biotechnology companies accounted for the largest share of the single-use bioprocessing market due to their higher adoption of single-use bioprocessing equipment and consumables, the stringent regulatory scenario, increased R&D activities, increased production of biologics, and rising manufacturing of biologics and biosimilars in developed countries.
Based on region, single-use bioprocessing market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the single-use bioprocessing market. Europe held the second largest share followed by the Asia Pacific. The Asia Pacific market is expected to show the highest growth rate during the forecast period. Growing pharmaceutical R&D activities, increasing demand for biosimilars, significant investments by biopharmaceutical companies & CMOs in emerging Asia Pacific countries, are some of the factors contributing to the regional growth.
Key players in the single-use bioprocessing market include Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Avantor, Inc. (US), 3M Company (US), Repligen Corporation (US), Entegris (US), Getinge AB (Sweden), Parker Hannifin Corporation (US), Alfa Laval Corporate AB (Sweden), Saint-Gobain (France), Eppendorf SE (Germany), Corning Incorporated (US), Eaton Corporation plc (Ireland)v, METTLER TOLEDO (US), Porvair PLC (UK), Lonza (Switzerland), ABEC, INC. (US), NewAge Industries (US), PBS Biotech, Inc. (US), Sentinel Process Systems, Inc. (US), Meissner Filtration Products, Inc. (US), SATAKE MultiMix Corporation (Japan), Hamilton Company (US), Membrane Solutions (US), Cole-Parmer Instrument Company, LLC (US), Distek, Inc. (US), Esco Lifesciences Group Ltd. (US), and TECNIC Bioprocess solutions (Spain).
Recent Developments of the Single Use Bioprocessing Industry:
In April 2024, Cytiva introduced the Xcellerex magnetic mixer, a single-use mixing system in 2,000 and 3,000 L capacities for large-scale mAb, vaccine, and genomic medicine manufacturing processes.
In April 2023, Merck KGaA launched the Ultimus single-use process container film designed to provide extreme durability and leak resistance for single-use assemblies used for bioprocessing liquid applications.
The global single-use bioprocessing market is experiencing explosive growth, projected to skyrocket from $8.2 billion in 2021 to $20.8 billion by 2026 at an impressive 20.5% compound annual growth rate (CAGR). This surge is fueled by the increasing demand for biopharmaceuticals, driven by an aging global population more susceptible to chronic conditions.
Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297
Single-use bioprocessing systems offer numerous advantages over traditional stainless-steel equipment, including greater energy efficiency, reduced water usage, smaller footprints, lower costs, quicker implementation, and diminished risk of cross-contamination. While concerns exist around extractables, leachables, and waste disposal, emerging markets in Asia like China and India present lucrative opportunities for this technology.
Major players like Sartorius, Danaher’s Cytiva, Thermo Fisher, and Merck are making massive investments to expand single-use bioprocessing capabilities and meet soaring demand for biologics and vaccines. Thermo Fisher alone invested over $475 million in 2020 to bolster its St. Louis facilities.
Sartorius Stedim Biotech held the leading position in the single-use bioprocessing market in 2020. Sartorius focuses on strengthening its position in the market by adopting organic and inorganic strategies such as product launches and expansions. During the past three years, Sartorius Stedim Biotech launched SUB systems such as BIOSTAT STR Generation 3 Single-Use Bioreactor, BIOSTAT RM TX Single-Use Bioreactor, and BIOSTAT STR. In 2019, Sartorius acquired Danaher’s Life Science portfolio, which is complementary to the portfolio of Sartorius’s laboratory and bioprocess business. In 2019, the company also expanded their operations in Puerto Rico.
Thermo Fisher Scientific is the second-largest player in the single-use bioprocessing market. Thermo Fisher Scientific operates in the single-use bioprocessing market through the life science solutions business segment. To further increase its share in the single-use bioprocessing market, the company focuses on growth strategies such as acquisitions and expansion. From 2019 to 2021, the company expanded its business in the US. The company also made investments worth ~USD 650 million from 2019 to 2021 to enhance their single-use bioprocessing capabilities and increase their market share.
The single-use media bags and containers segment currently dominates the market, driven by their widespread use across biomanufacturing processes. However, demand is strong across all application areas including filtration, storage, cell culture, mixing, and purification.
As biopharmaceutical production continues ramping up globally, the future looks extremely bright for flexible, cost-effective single-use bioprocessing solutions to unlock new manufacturing efficiencies and accelerate delivery of life-saving treatments.
Recent Developments of Single Use Bioprocessing Industry:
- In March 2020, Danaher acquired the Biopharma business from General Electric Company’s Life Sciences division. The business is called Cytiva, and is a standalone operating company within Danaher’s Life Sciences segment.
- In September 2020, Thermo Fisher Scientific invested more than USD 475 million in new capabilities at its St. Louis site to expand biologics development and manufacturing, cell and gene therapy capabilities, and drug product development capabilities.